Top Markets
#1 MowCat MowCat +49.06%
#2 Velvet Velvet +37.57%
#3 Derive Derive +21.24%
#4 Quack AI Quack AI +19.75%
#5 Audiera Audiera +18.76%
#6 Bermuda Shorts Bermuda Shorts +16.51%
#7 aPriori aPriori +14.44%
#8 Biconomy Biconomy +14.37%
#9 Geodnet Geodnet +12.49%
#10 Cross Cross +12.38%
Coin of the day
MowCat MowCat
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Aeterna Zentaris Inc. Aeterna Zentaris Inc.

Aeterna Zentaris Inc.

AEZS
Xếp hạng trong cổ phiếu #35469
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company,... Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone. Macimorelin is employed for diagnosing growth hormone deficiency in both adult and pediatric patients, and is also under investigation for various oncology indications. The drug is marketed commercially under the brand name Macrilen. The company engages in various licensing agreements, prominently with University Wuerzburg. This collaboration encompasses the research, development, manufacture, and commercialization of a prospective COVID-19 vaccine. It also involves developing, producing, and marketing a treatment for neuromyelitis optica spectrum disorder (NMOSD), establishing human 3D intestinal tissue models for infection biology research, and advancing pre-clinical work towards a potential Parkinson's disease therapy. Additionally, Aeterna Zentaris has formed licensing partnerships with Consilient Health Ltd., Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada. Another key collaboration is with The University of Sheffield in the United Kingdom, dedicated to the research, development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to treat primary hypoparathyroidism. Founded in 1990, Aeterna Zentaris Inc. maintains its corporate headquarters in Summerville, South Carolina.
Giá cổ phiếu
$3.97
Đồng bộ lần cuối: 2024-09-03
Vốn hóa thị trường
$3.86M
Thay đổi (1 ngày)
-1.00%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Aeterna Zentaris Inc. (AEZS)

Danh mục

Healthcare
Lịch sử chia tách cổ phiếu của Aeterna Zentaris Inc. (AEZS)
Cổ phiếu Aeterna Zentaris Inc. (mã: AEZS) đã trải qua tổng cộng 0 lần chia tách.
Lần chia tách gần nhất diễn ra vào ngày Aug 16, 2026.
Một cổ phiếu AEZS mua trước ngày Aug 16, 2026 hiện tương đương với 0 cổ phiếu AEZS.
Danh sách chia tách cổ phiếu
Năm Chia tách Tỷ lệ Tỷ lệ cộng dồn
Không đủ dữ liệu cho ngày được cung cấp.
Chia tách cổ phiếu của các công ty tương tự hoặc đối thủ
Công ty Số lần chia tách cổ phiếu Tỷ lệ cộng dồn Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE